David Harold Drewry
David Harold Drewry
Dirección de correo verificada de
Citado por
Citado por
Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor
B Lovejoy, A Cleasby, AM Hassell, K Longley, MA Luther, D Weigl, ...
Science 263 (5145), 375-377, 1994
Comprehensive characterization of the published kinase inhibitor set
JM Elkins, V Fedele, M Szklarz, KR Abdul Azeez, E Salah, J Mikolajczyk, ...
Nature biotechnology 34 (1), 95-103, 2016
New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource
I Pena, M Pilar Manzano, J Cantizani, A Kessler, J Alonso-Padilla, ...
Scientific reports 5 (1), 8771, 2015
Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition
NH Theodoulou, P Bamborough, AJ Bannister, I Becher, RA Bit, KH Che, ...
Journal of medicinal chemistry 59 (4), 1425-1439, 2016
Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement
JD Vasta, CR Corona, J Wilkinson, CA Zimprich, JR Hartnett, MR Ingold, ...
Cell chemical biology 25 (2), 206-214. e11, 2018
Solid‐supported reagents in organic synthesis
DH Drewry, DM Coe, S Poon
Medicinal research reviews 19 (2), 97-148, 1999
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery
P Bamborough, D Drewry, G Harper, GK Smith, K Schneider
Journal of medicinal chemistry 51 (24), 7898-7914, 2008
A public-private partnership to unlock the untargeted kinome
S Knapp, P Arruda, J Blagg, S Burley, DH Drewry, A Edwards, D Fabbro, ...
Nature chemical biology 9 (1), 3-6, 2013
Enhancements of screening collections to address areas of unmet medical need: an industry perspective
DH Drewry, R Macarron
Current opinion in chemical biology 14 (3), 289-298, 2010
Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B
P Chen, A Chaikuad, P Bamborough, M Bantscheff, C Bountra, C Chung, ...
Journal of medicinal chemistry 59 (4), 1410-1424, 2016
Progress towards a public chemogenomic set for protein kinases and a call for contributions
DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, ...
PloS one 12 (8), e0181585, 2017
Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS)
D H Drewry, T M Willson, W J Zuercher
Current topics in medicinal chemistry 14 (3), 340-342, 2014
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase
ND Adams, JL Adams, JL Burgess, AM Chaudhari, RA Copeland, ...
Journal of medicinal chemistry 53 (10), 3973-4001, 2010
Plasmodium kinases as targets for new-generation antimalarials
IS Lucet, A Tobin, D Drewry, AF Wilks, C Doerig
Future medicinal chemistry 4 (18), 2295-2310, 2012
Solid-phase synthesis of trisubstituted guanidines
DH Drewry, SW Gerritz, JA Linn
Tetrahedron letters 38 (19), 3377-3380, 1997
Donated chemical probes for open science
S Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, ...
Elife 7, e34311, 2018
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer
L Racioppi, ER Nelson, W Huang, D Mukherjee, SA Lawrence, W Lento, ...
Nature Communications 10 (1), 2450, 2019
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen
S Scheipl, M Barnard, L Cottone, M Jorgensen, DH Drewry, WJ Zuercher, ...
The Journal of pathology 239 (3), 320-334, 2016
The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification
CI Wells, H Al-Ali, DM Andrews, CRM Asquith, AD Axtman, I Dikic, ...
International journal of molecular sciences 22 (2), 566, 2021
Quantifying CDK inhibitor selectivity in live cells
CI Wells, JD Vasta, CR Corona, J Wilkinson, CA Zimprich, MR Ingold, ...
Nature communications 11 (1), 2743, 2020
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20